Watch Dr. Cash discuss the inclusion of XIFAXAN for IBS-D in the American College of Gastroenterology’s 2020 Clinical Guideline on Managing IBS

Brooks Cash, MD

Chief, Gastroenterology, Hepatology, and Nutrition
Dan and Lillie Sterling Professor of Medicine
UT Health Science Center at Houston

Watch Dr. Cash discuss the inclusion of XIFAXAN for the treatment of global IBS-D symptoms in the American College of Gastroenterology’s 2020 Clinical Guideline on Managing IBS.

IBS-D = irritable bowel syndrome with diarrhea

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.